$ cat ./records/gates-foundation-grand-challenges-grant-funds-oxitec-self-limitin-2010.txt
Gates Foundation Grand Challenges Grant Funds Oxitec Self-Limiting Aedes Aegypti for Dengue and Zika
[RECORD.TXT] · cat --full
The Gates Foundation awarded Oxitec $5 million through its Grand Challenges in Global Health initiative to advance field trials of self-limiting Aedes aegypti mosquitoes for dengue and Zika suppression. The OX513A Friendly Mosquito was subsequently deployed in trials in Brazil, the Cayman Islands, and Malaysia, achieving wild population suppression exceeding 90 percent in test zones. Success of this early grant directly seeded Oxitec's broader tropical disease mosquito-control platform and informed the foundation's decade-long bet on genetic insect biocontrol.
Source: https://www.labiotech.eu/trends-news/gates-foundation-oxitec-malaria-mosquito/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grand Challenges Grant to Johns Hopkins for Malaria Mosquito Kill-Switch Pathogen
Next →
Gates Foundation Invests in DHIS2 — Health Data System Now Used in 70+ Countries
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.